Authors: Stephenson K, Neuenschwander PF, Kurdowska AK, Pinson B, Price C.
Publication Year: 2008
Citation: Int J Pharm Compounding 2008;12(4):295-304.
In this randomized, placebo-controlled, double-blinded, crossover study, 30 postmenopausal women received either 20 mg/day transdermal progesterone or placebo for 4 weeks. Menopausal symptoms were significantly improved by the progesterone treatment compared to placebo, and no detrimental effects on any of the clotting or inflammatory factors were seen. This is in contrast to conventional hormone replacement with conjugated equine estrogens and synthetic progestins, which have been found to increase risk of thrombosis and inflammation and thereby impact cardiovascular risk. The authors conclude that transdermal progesterone is a safe alternative for the treatment of menopausal symptoms.